Kombiglyze XR is a once-daily extended-release oral antidiabetic medication that combines alogliptin and metformin. It is indicated for the treatment of type 2 diabetes mellitus to improve glycemic control. Alogliptin is a dipeptidyl-peptidase-4 inhibitor that enhances the activity of incretin hormones such as glp-1. Metformin is a biguanide that decreases hepatic glucose production and increases peripheral insulin sensitivity. Together they provide complementary mechanisms that lower fasting and postprandial blood glucose levels. Alogliptin promotes insulin secretion from pancreatic beta cells in response to elevated glucose. Metformin inhibits gluconeogenesis by reducing mitochondrial respiration and altering hepatic amp-activated protein kinase activity. The extended-release formulation provides sustained drug exposure resulting in consistent therapeutic effect throughout the day.

Kombiglyze XR is a prescription medication that combines saxagliptin and metformin in an extended-release formulation for the treatment of type 2 diabetes. Saxagliptin works by blocking the enzyme dipeptidyl-peptidase-4, which raises the levels of incretin hormones that stimulate insulin release when blood glucose is high. The increased incretin activity also suppresses glucagon secretion, further reducing glucose production after meals. Metformin is released slowly and acts primarily in the liver to decrease gluconeogenesis and improve peripheral insulin sensitivity. Together the two agents lower fasting and post-prandial glucose concentrations without causing excessive hypoglycemia. Pharmacodynamically the combination provides complementary mechanisms that enhance glucose-dependent insulin secretion and reduce hepatic glucose output. This coordinated action underlies the drug's therapeutic effect of improving overall glycemic control in patients with type 2 diabetes.

Kombiglyze XR is an antidiabetic medication used to improve blood sugar control in people with type 2 diabetes mellitus. Like many prescription drugs, it can cause side effects that are generally mild and may resolve on their own. The most frequently reported adverse reactions include headache, dizziness, and nausea. Some individuals may experience mild gastrointestinal discomfort such as abdominal pain or diarrhea. Hypoglycemia is less common when Kombiglyze XR is used alone but can occur if it is combined with other glucose-lowering agents. Fluid retention leading to swelling of the legs or feet is a rare but documented effect. Laboratory monitoring may occasionally reveal elevated liver enzymes, which typically return to normal with continued treatment.

Kombiglyze XR may cause nausea in some patients. It can also lead to headache or dizziness. Some users experience flushing of the skin. Mild low blood sugar episodes have been reported. Occasional gastrointestinal discomfort such as abdominal pain occurs. Fatigue is another possible side effect. Most reactions are mild and temporary. Serious adverse events are rare.